Bristol Myers Squibb
4Q Revenues: $11.5 billion (+1%) 
4Q Earnings: $1.8 billion (-13%)
FY Revenues: $45.0 billion (-2%) 
FY Earnings: $8.0 billion (+27%)
Comments: Higher sales of new product portfolio, as well as Eliquis and Opdivo sales, were partially offset by lower sales of Revlimid, down 38% to $1.5 billion. Total In-Line Products were up 5% to $8.7 billion. Eliquis sales were $2.9 billion in the quarter, up 7%. Opdivo sales were $2.4 billion, up 8%. Orencia sales were $985 million, up 8%. Pomalyst/Imnovid sales were $890 million, up 1%. Yervoy sales were flat at $566 million. Sprycel sales were $526 million, down 9%. New product portfolio sales were up 66% to $645 million. Reblozyl sales were up 61% to $199 million. Opdualag sales were up 83% to $104 million. Zeposia sales were up 68% to $133 million, and Breyanzi sales were up 84% to $55 million.